{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:15:57Z","timestamp":1791825357936,"version":"4.3.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The first decompensation event of cirrhosis is a critical point of disease progression, and the incidence of further decompensation occurs up to more than 50%. Fuzheng Huayu tablet is used as a classic anti-hepatic fibrosis herbal compound. There is no randomized controlled trial (RCT) combining Fuzheng Huayu tablet with antiviral to prevent the occurrence of further decompensation. The aim of this study was to conduct a prospective randomized, double-blind, placebo-controlled, multicenter study to investigate its safety and efficacy in terms of the risk of further decompensation events in patients with first decompensation, and to fill the gap of evidence-based medicine in this field.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This study aims to conduct a prospective, multicenter, double-blind, randomized, placebo-controlled trial. The planned sample size is 432 patients, with the ratio of the Fuzheng Huayu group to the placebo control group being 1:1. Participants will be randomly assigned to the two groups using a stratified block randomization method at the central level. The Fuzheng Huayu group (Fuzheng Huayu tablets combined with conventional antiviral therapy) and the placebo group (placebo combined with conventional antiviral therapy) will be treated for 48 weeks and followed up to 96 weeks. The study period will last for a total of 2 years. The cumulative incidence of further decompensation events within 1-year, the cumulative incidence of recompensation within 1-year, the incidence of liver failure, hepatocellular carcinoma, and liver disease-related deaths will be analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will be a prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the clinical benefit of Fuzheng Huayu tablets in the risk of further decompensation events in patients with first decompensation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      Clinical Trials.gov, study ID\n                      <jats:ext-link>NCT07017426<\/jats:ext-link>\n                      ; International Traditional Medicine Clinical Trial Registry, registration number\n                      <jats:ext-link>ITMCTR2025001365<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1828944","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:30:14Z","timestamp":1783006214000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Fuzheng Huayu tablets reduces the risk of further decompensation after the first decompensation in patients with HBV-related cirrhosis: protocol for a randomized, double-blind, placebo-controlled, multicenter trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Lihua","family":"Yu","sequence":"first","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Peng","sequence":"additional","affiliation":[{"name":"Science and Technology Department, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxin","family":"Shi","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Ma","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnan","family":"Li","sequence":"additional","affiliation":[{"name":"Science and Technology Department, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Liver Disease, Qingdao Public Health Clinical Center","place":["Qingdao, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Tianjin Second People\u2019s Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Hou","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Yang","sequence":"additional","affiliation":[{"name":"Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"108846","DOI":"10.1016\/j.biopha.2019.108846","article-title":"The effect and mechanisms of fuzheng huayu formula against chronic liver diseases","volume":"114","author":"Chen","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.hbpd.2022.03.007","article-title":"Impact of fuzheng huayu tablet on antiviral effect of entecavir in patients with hepatitis B cirrhosis","volume":"21","author":"Cheng","year":"2022","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1097\/HEP.0000000000000652","article-title":"Further decompensation in cirrhosis: results of a large multicenter cohort study supporting baveno VII statements","volume":"79","author":"D'Amico","year":"2024","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - Renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J. Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.14218\/JCTH.2023.00521","article-title":"Beneficial effects of traditional Chinese medicine fuzheng huayu on the occurrence of hepatocellular carcinoma in patients with compensated chronic hepatitis B cirrhosis receiving entecavir: a multicenter retrospective cohort study","volume":"12","author":"Fan","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.cgh.2020.08.064","article-title":"Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B","volume":"19","author":"Lee","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11655-020-3257-6","article-title":"Treatment of HBV cirrhosis with fuzheng huayu tablet and entecavir: design of a randomized, double-blind, parallel and multicenter clinical trial","volume":"27","author":"Li","year":"2021","journal-title":"Chin. J. Integr. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabine\/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.3748\/wjg.v11.i19.2892","article-title":"Multicenter clinical study on fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B","volume":"11","author":"Liu","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1749-8546-4-12","article-title":"Effect of fuzheng huayu formula and its actions against liver fibrosis","volume":"4","author":"Liu","year":"2009","journal-title":"Chin. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13020-023-00754-4","article-title":"Cyp4a12-mediated retinol metabolism in stellate cells is the antihepatic fibrosis mechanism of the Chinese medicine fuzheng huayu recipe","volume":"18","author":"Ping","year":"2023","journal-title":"Chin. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"117001","DOI":"10.1016\/j.jep.2023.117001","article-title":"Fuzheng huayu recipe alleviates liver fibrosis via inhibiting NLRP3 inflammasome activation in macrophages","volume":"318","author":"Ping","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.dld.2022.12.014","article-title":"The baveno VII concept of cirrhosis recompensation","volume":"55","author":"Reiberger","year":"2023","journal-title":"Dig. Liver Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3760\/cma.j.cn501113-20230620-00268","article-title":"Fuzheng huayu capsules reducing development of hepatocellular carcinoma in cirrhotic patients with chronic hepatitis B based on the ratio of neutrophils\/lymphocytes","volume":"31","author":"Shi","year":"2023","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s11655-021-3293-x","article-title":"Active components formulation developed from fuzheng huayu recipe for anti-liver fibrosis","volume":"28","author":"Sun","year":"2022","journal-title":"Chin. J. Integr. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ptr.6009","article-title":"Fuzheng huayu capsule as an adjuvant treatment for HBV-Related cirrhosis: a systematic review and meta-analysis","volume":"32","author":"Wang","year":"2018","journal-title":"Phytother. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jhep.2022.07.037","article-title":"Validation of baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis","volume":"77","author":"Wang","year":"2022","journal-title":"J. Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00535-021-01788-x","article-title":"Evidence-based clinical practice guidelines for liver cirrhosis 2020","volume":"56","author":"Yoshiji","year":"2021","journal-title":"J. Gastroenterol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/10286020.2024.2355132","article-title":"Regulation of fuzheng huayu capsule on inhibiting the fibrosis-associated hepatocellular carcinogenesis","volume":"26","author":"Zhang","year":"2024","journal-title":"J. Asian Nat. Prod. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"115599","DOI":"10.1016\/j.jep.2022.115599","article-title":"Efficacy and safety of fuzheng huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: a single arm clinical objective performance criteria trial","volume":"298","author":"Zhao","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"118018","DOI":"10.1016\/j.jep.2024.118018","article-title":"Progress in clinical and basic research of fuzheng huayu formula for the treatment of liver fibrosis","volume":"327","author":"Zhou","year":"2024","journal-title":"J. Ethnopharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1828944\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:30:19Z","timestamp":1783006219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1828944\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":22,"alternative-id":["10.3389\/fphar.2026.1828944"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1828944","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"article-number":"1828944"}}